BR9710988A - Método e compostos moduladores receptores de androgênio - Google Patents

Método e compostos moduladores receptores de androgênio

Info

Publication number
BR9710988A
BR9710988A BR9710988-6A BR9710988A BR9710988A BR 9710988 A BR9710988 A BR 9710988A BR 9710988 A BR9710988 A BR 9710988A BR 9710988 A BR9710988 A BR 9710988A
Authority
BR
Brazil
Prior art keywords
compounds
androgen receptor
disclosed
modulating method
receptor modulating
Prior art date
Application number
BR9710988-6A
Other languages
English (en)
Inventor
James P Edwards
Robert Higuchi
Todd Jones
Original Assignee
Ligand Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ligand Pharm Inc filed Critical Ligand Pharm Inc
Publication of BR9710988A publication Critical patent/BR9710988A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Electrotherapy Devices (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)

Abstract

"MéTODOS E COMPOSTOS MODULADORES RECEPTORES DE ANDROGêNIO". São descritos compostos não esteróides com alta afinidade, moduladores de alta seletividade, para receptores de androgênio. Também são apresentadas composições farmacêuticas feitas a partir de tais compostos, métodos para o emprego dos compostos apresentados, e composições para tratamento de pacientes necessitando de agonista receptor de androgênio, agonista parcial ou terapia antagónica, intermediários úteis no preparo de compostos e processos para a preparação de compostos moduladores receptores de androgênio.
BR9710988-6A 1996-06-27 1997-06-26 Método e compostos moduladores receptores de androgênio BR9710988A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2199796P 1996-06-27 1996-06-27
PCT/US1997/011222 WO1997049709A1 (en) 1996-06-27 1997-06-26 Androgen receptor modulator compounds and methods

Publications (1)

Publication Number Publication Date
BR9710988A true BR9710988A (pt) 2002-01-15

Family

ID=21807289

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9710988-6A BR9710988A (pt) 1996-06-27 1997-06-26 Método e compostos moduladores receptores de androgênio

Country Status (12)

Country Link
EP (1) EP0918774B9 (pt)
JP (1) JP2000513362A (pt)
AT (1) ATE209207T1 (pt)
AU (1) AU728178B2 (pt)
BR (1) BR9710988A (pt)
DE (1) DE69709752T2 (pt)
DK (1) DK0918774T3 (pt)
ES (1) ES2168650T3 (pt)
NO (1) NO311645B1 (pt)
PT (1) PT918774E (pt)
RU (1) RU2214412C2 (pt)
WO (1) WO1997049709A1 (pt)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6826407B1 (en) 1999-03-29 2004-11-30 Richard J. Helferich System and method for integrating audio and visual messaging
US6253061B1 (en) 1997-09-19 2001-06-26 Richard J. Helferich Systems and methods for delivering information to a transmitting and receiving device
US6636733B1 (en) 1997-09-19 2003-10-21 Thompson Trust Wireless messaging method
US7003304B1 (en) 1997-09-19 2006-02-21 Thompson Investment Group, Llc Paging transceivers and methods for selectively retrieving messages
US6983138B1 (en) 1997-12-12 2006-01-03 Richard J. Helferich User interface for message access
US6472415B1 (en) * 1998-12-18 2002-10-29 Biophysica, Inc. Androgen receptor suppressors in the therapy and diagnosis of prostate cancer, alopecia and other hyper-androgenic syndromes
US6566372B1 (en) 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
US6667313B1 (en) 1999-08-27 2003-12-23 Ligand Pharmaceuticals Inc. 8-substituted-6-triflouromethyl-9-pyrido [3,2-G] quinoline compounds as androgen receptor modulators
PL353792A1 (en) * 1999-08-27 2003-12-01 Ligand Pharmaceuticals Incorporatedligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
WO2001019770A2 (en) 1999-09-14 2001-03-22 Ligand Pharmaceuticals Incorporated Rxr modulators with improved pharmacologic profile
DE60045751D1 (de) 1999-09-30 2011-04-28 Harbor Biosciences Inc Therapeutische Behandlung androgenrezeptorbedingter Leiden
AU2001230606A1 (en) * 2000-02-10 2001-08-20 Chugai Seiyaku Kabushiki Kaisha Method of screening antiandrogen agent
JP2004509072A (ja) 2000-06-28 2004-03-25 ブリストル−マイヤーズ　スクイブ　カンパニー 選択的アンドロゲン受容体モジュレーター並びにその同定、設計及び使用方法
US7001911B2 (en) 2000-06-28 2006-02-21 Bristol-Myers Squibb Company Fused cyclic modulators of nuclear hormone receptor function
US20040077605A1 (en) 2001-06-20 2004-04-22 Salvati Mark E. Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
WO2002000653A2 (en) * 2000-06-28 2002-01-03 Bristol-Myers Squibb Company Fused cyclic compounds as modulators of nuclear hormone receptor function
AU2001267904A1 (en) 2000-06-30 2002-01-14 Chugai Seiyaku Kabushiki Kaisha Novel antiandrogenic agent
JP4966477B2 (ja) * 2000-09-19 2012-07-04 ブリストル−マイヤーズ スクイブ カンパニー 核ホルモン・レセプタ機能のモジュレーターである、縮合複素環式スクシンイミド化合物およびその類縁体
US6953679B2 (en) 2000-09-19 2005-10-11 Bristol-Myers Squibb Company Method for the preparation of fused heterocyclic succinimide compounds and analogs thereof
US7214690B2 (en) 2001-02-23 2007-05-08 Ligand Pharmaceuticals Incorporated Tricyclic quinolinone and tricyclic quinoline androgen receptor modulator compounds and methods
US7026484B2 (en) 2001-02-23 2006-04-11 Ligand Pharmaceuticals Incorporated Tricyclic androgen receptor modulator compounds and methods
CA2463311A1 (en) * 2001-10-19 2003-05-01 Paul J. Coleman Androgen receptor modulators and methods of use thereof
AU2002364082A1 (en) 2001-12-19 2003-07-09 Bristol-Myers Squibb Company Fused heterocyclic compounds and analogs thereof: modulators of nuclear hormone receptor function
WO2003057669A1 (fr) * 2001-12-28 2003-07-17 Takeda Chemical Industries, Ltd. Antagonistes du recepteur androgene
KR101088352B1 (ko) 2002-02-28 2011-11-30 유니버시티 오브 테네시 리서치 파운데이션 다치환된 선택적 안드로겐 수용체 조절자 및 이를 사용하는 방법
AU2003230869B2 (en) * 2002-04-26 2010-02-25 Ortho-Mcneil Pharmaceutical, Inc. 2-(quinolonyl)-fused heterocycles as androgen receptor modulators
US7405234B2 (en) 2002-05-17 2008-07-29 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
DE20301728U1 (de) 2002-10-11 2004-03-11 Ligand Pharmaceuticals, Inc., San Diego 5-substituierte 7,9-Difluor-5H-Chromeno(3,4-f) -Chinolin-Verbindungen als selektive Progesteronrezeptormodulator-Verbindungen
EP1567487A4 (en) 2002-11-15 2005-11-16 Bristol Myers Squibb Co OPEN-CHAINED, PROLYL-FROSTED MODULATORS OF ANDROGEN RECEPTOR FUNCTION
WO2004065379A1 (en) 2003-01-17 2004-08-05 Warner-Lambert Company Llc Androgen receptor antagonists
JP4709759B2 (ja) 2003-08-22 2011-06-22 リガンド・ファーマシューティカルズ・インコーポレイテッド アンドロゲン受容体モジュレーター化合物としての６−シクロアミノ−２−キノリノン誘導体
US7256208B2 (en) 2003-11-13 2007-08-14 Bristol-Myers Squibb Company Monocyclic N-Aryl hydantoin modulators of androgen receptor function
US7820702B2 (en) 2004-02-04 2010-10-26 Bristol-Myers Squibb Company Sulfonylpyrrolidine modulators of androgen receptor function and method
US7625923B2 (en) 2004-03-04 2009-12-01 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
US7696241B2 (en) 2004-03-04 2010-04-13 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
US7388027B2 (en) 2004-03-04 2008-06-17 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
US8519158B2 (en) 2004-03-12 2013-08-27 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
DE602007007734D1 (de) * 2006-02-10 2010-08-26 Janssen Pharmaceutica Nv Neue imidazolopyrazolderivate als selektive androgen-rezeptor-modulatoren
RU2381229C2 (ru) * 2007-10-17 2010-02-10 Государственное образовательное учреждение высшего профессионального образования "Пермская государственная фармацевтическая академия Федерального агентства по здравоохранению и социальному развитию" (ГОУ ВПО ПГФА Росздрава) 11b-(ГEТ)АРИЛ-2,3,6,11b-ТЕТРАГИДРООКСАЗОЛО[2',3':2,1]ПИРРОЛО[3,4-b]ХИНОЛИН-5,11-ДИОНЫ И СПОСОБ ИХ ПОЛУЧЕНИЯ
MX2010009162A (es) 2008-02-22 2010-12-21 Radius Health Inc Moduladores selectivos del receptor de androgeno.
US8268872B2 (en) 2008-02-22 2012-09-18 Radius Health, Inc. Selective androgen receptor modulators
EP2130831A1 (en) 2008-06-06 2009-12-09 InterMed Discovery GmbH CDC25 inhibitors
EP2426133B1 (en) * 2009-04-30 2015-12-16 Nissan Chemical Industries, Ltd. Novel crystal forms of tricyclic benzopyran compound and processes for producing same
CA2788907A1 (en) 2010-02-04 2011-08-11 Radius Health, Inc. Selective androgen receptor modulators
PT2568806T (pt) 2010-05-12 2016-08-05 Radius Health Inc Regimes terapêuticos
US8642632B2 (en) 2010-07-02 2014-02-04 Radius Health, Inc. Selective androgen receptor modulators
ES2550319T3 (es) 2010-09-28 2015-11-06 Radius Health, Inc Moduladores selectivos del receptor de andrógenos
BR112013018534B1 (pt) 2011-01-20 2021-04-06 Board Of Regents, The University Of Texas System Agente de contraste, seus métodos de preparação, e produto de combinação
RS67458B1 (sr) 2014-03-28 2025-12-31 Univ Duke Lečenje kancera dojke pozitivnog na receptor estrogena upotrebom selektivnih modulatora receptora estrogena
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
RS63311B1 (sr) 2016-06-22 2022-07-29 Ellipses Pharma Ltd Ar+ metode lečenja raka dojke
CN106397317B (zh) * 2016-09-26 2019-03-22 天津师范大学 1,2,3,4-四氢喹啉化合物及其合成方法与应用
CN106565723B (zh) * 2016-11-04 2019-08-27 江苏师范大学 一种呋喃并吡啶、苯并吡啶类衍生化合物的制备方法
KR102881465B1 (ko) 2017-01-05 2025-11-04 래디어스 파마슈티컬스, 인코포레이티드 Rad1901-2hcl의 다형 형태
KR20220003554A (ko) 2019-04-19 2022-01-10 리간드 파마슈티칼스 인코포레이티드 화합물의 결정질 형태 및 결정질 형태를 제조하는 방법
CN116969959B (zh) * 2023-08-03 2025-10-31 浙江大学 取代四氢喹啉类衍生物及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5856090A (en) * 1989-07-07 1991-02-06 Endorecherche Inc. Androgen derivatives for use in the inhibition of sex steroid activity
ATE136898T1 (de) * 1991-10-29 1996-05-15 Glaxo Wellcome Inc Wasserlösliche camptothecinderivate
US5677336A (en) * 1993-10-21 1997-10-14 Ligand Pharmaceuticals Incorporated Non-steroid androgen receptor antagonist compounds and methods
WO1996019458A2 (en) * 1994-12-22 1996-06-27 Ligand Pharmaceuticals Incorporated Steroid receptor modulator compounds and methods

Also Published As

Publication number Publication date
DK0918774T3 (da) 2002-05-21
RU2214412C2 (ru) 2003-10-20
ATE209207T1 (de) 2001-12-15
WO1997049709A1 (en) 1997-12-31
PT918774E (pt) 2002-05-31
NO986100D0 (no) 1998-12-23
EP0918774B1 (en) 2001-11-21
EP0918774A1 (en) 1999-06-02
DE69709752T2 (de) 2002-07-18
EP0918774B9 (en) 2002-04-10
AU3508497A (en) 1998-01-14
AU728178B2 (en) 2001-01-04
NO311645B1 (no) 2001-12-27
JP2000513362A (ja) 2000-10-10
ES2168650T3 (es) 2002-06-16
DE69709752D1 (de) 2002-02-21
NO986100L (no) 1998-12-23

Similar Documents

Publication Publication Date Title
ES2168650T3 (es) Compuestos y metodos moduladores de receptores de androgenos.
BR9510486A (pt) Compostos moduladores de receptores de esteróide e métodos
MX9704640A (es) Compuesto moduladores de los receptores de los esteroides y metodos para su preparacion.
WO2000066590A3 (en) Tetracyclic progesterone receptor modulator compounds and methods
ATE245993T1 (de) Allosterische modulatoren des nmda-rezeptors
DK0873295T3 (da) Dimer-selektive RXR-modulatorer og fremgangsmåder til deres anvendelse
YU7797A (sh) Kombinovana terapija za osteoporozu
YU18400A (sh) Prostaglanidin agonisti i njihova primena za tretiranje koštanih poremećaja
DK0773962T3 (da) Antistoffer, som aktiverer en erythropoietinreceptor
EP0911321A3 (en) Compounds for the treatment of osteoporosis
TR200100922T2 (tr) Aktif maddelerin akciğerler yolu ile tatbik edilmesi.
AP9801269A0 (en) Prostaglandin agonists.
CH1196397H1 (de) Metabotrope Glutamatrezeptorantagonisten zur Behandlung von Krankheiten des zentralen Nervensystems.
DK0874625T3 (da) Indanderivater til antipsykotiske præparater
BR9708347A (pt) Compostos de tetrahidorbeta-carbonila
DK0996435T3 (da) Aminosyrederivater anvendelige til behandling af slagtilfælde
CA2259031A1 (en) Androgen receptor modulator compounds and methods

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFERIMENTO DO PRESENTE PEDIDO, UMA VEZ QUE O REQUERENTE NAO CUMPRIU COMPLETAMENTE AS EXIGENCIASDESTE INSTITUTO, PERMANECE O OBICE AO PATENTEAMENTO POIS A MATERIA PLEITEADA CONTINUA EM DESACORDO COM OS ARTIGOS 24 E 25 DA LPI

B12B Appeal against refusal [chapter 12.2 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07F Notification of approval that there is no relation to art. 229 of lpi (pipeline patents) [chapter 7.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]